Seagen Inc (SGEN)

[surf1944]

9:02AM Seattle Genetics highlights ADCETRIS (Brentuximab Vedotin) clinical data in the frontline setting at the International Symposium on Hodgkin Lymphoma; data frm ADCETRIS Phase 1 Frontline Hodgkin Lymphoma clinical trial support enrollment of ongoing global phase 3 ECHELON-1 clinical trial for patients with advanced frontline HL (SGEN) 40.70 : Co highlighted multiple ADCETRIS (brentuximab vedotin) data presentations at the 9th International Symposium on Hodgkin Lymphoma (ISHL) being held October 12-15, 2013 in Cologne, Germany. ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30, which is expressed in classical Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (sALCL). ADCETRIS was granted accelerated approval by the U.S. Food and Drug Administration (FDA) in August 2011 for relapsed HL and sALCL and conditional marketing authorization by the European Commission in October 2012 for relapsed or refractory HL and sALCL.

Three oral and nine poster presentations at ISHL illustrate the broad clinical development program for ADCETRIS in HL, including data from a phase 1 frontline advanced HL trial and a poster presentation describing the ongoing global phase 3 ECHELON-1 clinical trial in frontline HL. ADCETRIS is currently not approved for use in the treatment of newly diagnosed HL